



Table S1. Clinical outcomes 12-months follow-up.

Clinical Outcome	Total (n = 132)	No antithrombotic Treatment (n = 6)	Single Antiplatelet (n = 75)	Dual Antiplatelet (n = 39)	Apixaban 2.5mg/12 h (n = 12)	p Value
Ischemic stroke	1 (1)	0	1 (1)	0	0	0.33
Systemic Embolization	0	0	0	0	0	NA
Device related thrombus	5 (4)	1 (16)	0	2 (5)	0	0.02
Any Bleeding (major + minor)	9 (7)	0	4 (5)	5 (13)	1 (8)	0.53
Major bleeding (BARC $\geq 3$ )	5 (4)	0	2 (3)	3 (8)	0	0.65
All-cause mortality	6 (4)	0	4 (6)	2 (5)	0	0.73

Values are n (%) or mean  $\pm$  SD.

Figure S1. Antithrombotic treatment after three-months follow-up.

